Takeda, Cantel & more: 3 GI company key notes

Here are three updates from gastroenterology companies from the past week:

Takeda's ulcerative colitis drug Entyvio was one of the key products behind a 4.2 percent increase in underlying revenue. Takeda reported 880.6 billion yen in revenue ($7.82 billion).

Cantel Medical Group appointed Bill Haydon as senior vice president and general manager of the company's medical division.

The Toronto Stock Exchange approved CRH Medical's intention to renew its normal course issuer bid.

More articles on gastroenterology:
Study finds advanced adenomas similarly prevalent in white, black populations
West Virginia gastroenterologist sentenced to prison for sexually abusing patients — 5 insights
CRH Medical renews normal course issuer bid — 3 insights


© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months